Preferred Label : Talazoparib Tosylate;

NCIt definition : The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.;

UNII : 02WK9U5NZC;

InChIKey : QUQKKHBYEFLEHK-QNBGGDODSA-N;

CAS number : 1373431-65-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1373431-65-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Talzenna;

NCI Metathesaurus CUI : CL553698;

Details


Main resources

You can consult :


https://ansm.sante.fr/actualites/avis-de-lansm-du-20-11-2023-sur-le-medicament-talzenna-dans-le-cadre-dune-demande-daap
2023
false
false
false
France
French
drug information
talazoparib
Talazoparib Tosylate
prostatic neoplasms, Castration-Resistant
metastatic castration resistant prostate cancer
talazoparib

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.